TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES

(19)

(11)

EP 3 368 080 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	26.04.2023 Bulletin 2023/17

(45)	Mention of the grant of the patent:
	22.03.2023 Bulletin 2023/12

(21)	Application number: 16861054.1

(22)	Date of filing: 31.10.2016

(51)

International Patent Classification (IPC):

A61K 31/455^(2006.01)
A61P 25/28^(2006.01)
C07C 57/30^(2006.01)
A61P 25/00^(2006.01)
A61K 31/192^(2006.01)
A61K 9/00^(2006.01)

A61K 45/06^(2006.01)
C07C 57/03^(2006.01)
C07C 57/50^(2006.01)
A61P 25/16^(2006.01)
A61K 31/198^(2006.01)
A61K 9/48^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 9/0019; A61K 9/48; A61K 45/06; A61K 31/455; A61P 25/00; A61P 25/16; A61P 25/28; A61K 9/0043; A61K 9/0053; A61K 31/192; A61K 31/198; Y02A 50/30

	C-Sets:
	A61K 31/192, A61K 2300/00; A61K 31/198, A61K 2300/00; A61K 31/455, A61K 2300/00;

(86)	International application number:
	PCT/US2016/059770

(87)	International publication number:
	WO 2017/075607 (04.05.2017 Gazette 2017/18)

(54)

TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES

BEHANDLUNG VON ERKRANKUNGEN DES NERVENSYSTEMS MITHILFE VON KOMBINATIONEN VON RXR-AGONISTEN UND SCHILDDRÜSENHORMONEN

TRAITEMENT DES TROUBLES DU SYSTÈME NERVEUX AU MOYEN DE COMBINAISONS D'AGONISTES DE PXR ET D'HORMONES THYROÏDIENNES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

31.10.2015 US 201562249216 P

(43)	Date of publication of application:
	05.09.2018 Bulletin 2018/36

(73)	Proprietor: IO Therapeutics, Inc.
	Spring, TX 77387 (US)

(72)	Inventors:
	CHANDRARATNA, Roshantha, A. San Juan Capistrano, CA 92675 (US) SANDERS, Martin, E. Seattle, WA 98101 (US)

(74)	Representative: Murgitroyd & Company
	Murgitroyd House 165-169 Scotland Street Glasgow G5 8PL Glasgow G5 8PL (GB)

(56)

References cited: :

EP-A1- 2 322 147
WO-A1-2015/059632
US-A1- 2009 227 674
US-A1- 2015 038 585

EP-A1- 2 556 827
US-A1- 2004 147 611
US-A1- 2009 227 674

C. ASSAF ET AL: "Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion", BRITISH JOURNAL OF DERMATOLOGY, vol. 155, no. 2, 1 August 2006 (2006-08-01), pages 261-266, XP055586558, UK ISSN: 0007-0963, DOI: 10.1111/j.1365-2133.2006.07329.x
AI LING FU ET AL: "Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease", NEUROPHARMACOLOGY., vol. 58, no. 4-5, 1 March 2010 (2010-03-01), pages 722-729, XP055593277, GB ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2009.12.020
SHERMAN ET AL.: 'Central hypothyroidism associated with retinoid X receptor-selective ligands.' THE NEW ENGLAND JOURNAL OF MEDICINE, [Online] vol. 340, no. 14, 1999, pages 1075 - 1079, XP055379565 Retrieved from the Internet: <URL:http://www.nejm.org/doi/pdf/10.1056/NE JM199904083401404> [retrieved on 2016-12-12]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).